Chromosome region 2q33 encodes several regulators of the immune system, among these the CD28, CTLA4 and ICOS molecules. Involvement of these genes in multiple sclerosis (MS) is not yet clear. We investigated six microsatellites and three SNPs in a relatively large and clinically well characterised Norwegian MS cohort. No associations were observed for any of the markers analysed in 575 MS patients and 551 controls. Associations were neither found when stratifying the material for the HLA-DRB1*1501, DQB1*0602 haplotype, gender, age at onset, disease course nor familial aggregation. In conclusion, this study could not confirm association with the CD28/CTLA4/ICOS gene region. D
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Both environmental and genetic factors contribute to the disease. The HLA class II region is the only region that is firmly established to be associated with MS (Olerup and Hillert, 1991; Spurkland et al., 1991) , however, the genetic susceptibility probably involves many different genes (Dyment et al., 2004) .
Genes involved in T cell regulation have been investigated as some of the most interesting candidate genes in autoimmune diseases, among these are the cluster of differentiation molecule 28 (CD28) gene, the cytotoxic T lymphocyte antigen 4 (CTLA4) gene and the inducible co-stimulatory molecule (ICOS) gene located on chromosome 2q33. Especially, the CTLA4 gene has been shown to be linked to and associated with several autoimmune diseases (for review, see Kristiansen et al., 2000) . Recently, the CT60 single nucleotide polymorphism (SNP), located in the CTLA4 region, was reported to be involved in Graves_ disease, autoimmune hypothyroidism and type 1 diabetes (Ueda et al., 2003) .
Since we published the first report on an association with the CTLA4+49 polymorphism in MS (Harbo et al., 1999) , a series of genetic analyses of the CTLA4 gene and other closely located genes have been reported in MS (for overview; see Holopainen and Partanen, 2001; Kristiansen et al., 2000; Teutsch et al., 2004) . The results obtained in these studies have, however, been inconsistent. In the present study, we therefore aimed at extending our previous analysis of CTLA4 polymorphisms, both by genotyping more markers in the CD28, CTLA4 and ICOS gene regions
